Birx Says WH Coronavirus Task Force Preparing to Review Distribution of Remdesivir, Email Shows

White House coronavirus coordinator Dr. Deborah Birx is revealing that mistakes were made in the government’s decision making that led to errors in the allocation of the drug Remdesivir, which is currently being touted as a potential treatment for coronavirus.

According to an email Birx sent to members of the coronavirus task force and senior White House officials including infectious disease expert, Dr. Anthony Fauci, a review of the decision-making will take place, according to The Wall Street Journal, who was read the email by an official.

Birx said it will be reviewed in order to pinpoint where the “misalignment” occurred.

“We can later review the decision-making process, the lack of engagement of Task Force, and the methodology and analysis used by the data and modeling group that resulted in the misalignment of the therapeutic and on-the-ground current need in the first shipment so we can be assured this doesn’t occur in the future,” Dr. Birx said in the email from May 7.

Two days after Birx’s email, the government implemented changes to how the drug is allocated. In a statement released on Saturday, the Department of Health and Human Services confirmed states would now be in charge of the allocation of the drug.

The department said the government will be shipping the drug to states and then states would distribute the drug to health systems on an as-needed basis.